The following articles (labelled with PubMed ID or TBD) are for your review
||Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).
||Icahn School of Medicine at Mount Sinai
||Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
||Vanderbilt University Medical Center
||A quantitative analysis of kinase inhibitor selectivity.
||Comprehensive analysis of kinase inhibitor selectivity.
||Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factorß receptor I (TGFßRI).
||Boehringer Ingelheim Pharma GmbH& Co KG
||AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
||[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.
||Novartis Pharma AG